Sage Partners

Investor type Accelerator
Founders John Gaulding

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 6
Average round size
info
The average size of a deal this fund participated in
$125M
Portfolio companies 6
Rounds per year 0.30
Lead investments 0
Key employees Soon

Areas of investment

  • Biotechnology
  • Pharmaceutical
  • Health Care
  • Therapeutics
  • Medical

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Sage Partners:
Typical Co-investors
Sage Partners is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Sage Partners:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Acorn Bioventures New York, New York, United States
Ascend Capital Partners -
At One Ventures -
Barco Healthcare -
Emurgo Japan, Tokyo
Flybridge Capital Partners Boston, Massachusetts, United States
Garden State Life Sciences Venture Pennsylvania, Philadelphia, United States
Impact Ventures Hungary Budapest, Hungary
JOLT Canada, Ontario, Toronto
Koch Equity Development Kansas, United States, Wichita
Naseel -
National Building and Marketing Ar Riyad, Riyadh, Saudi Arabia
Radianx Capital -
Sustainable Ventures England, London, United Kingdom
TechSquare Labs Atlanta, Georgia, United States
The Refiners California, San Francisco, United States
Vetrargil Gullbringusysla, Iceland, Reykjavík
Zhuhai Gaoxin Chuangye Touzi Co., Ltd. -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

ShouTi

Biotechnology
Health Care
Medical
Pharmaceutical
Product Research
$100M20 Oct 2021 Shanghai, China

WT Microtech Medical

$153M06 Oct 2021 Hangzhou, Zhejiang, China

Visus Therapeutics

Biotechnology
Therapeutics
$20M10 Aug 2021 Seattle, Washington, United States

Insilico Medicine

Artificial Intelligence
Biotechnology
Genetics
Health Care
Pharmaceutical
$255M22 Jun 2021 Hong Kong Island, Hong Kong, China

Abbisko Therapeutics

Health Care
Pharmaceutical
Therapeutics
$123M07 Jan 2021 China, Shanghai

Harbour Biomed

Biopharma
Biotechnology
Pharmaceutical
$102M09 Jul 2020 China, Shanghai
News
ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform

– ShouTi Inc. announced the close of a $100m Series B financing round.
– The round was led by BVF Partners. Additional new investors include Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Lilly Asia Ventures, Monashee Capital, Sage Partners, Stork Capital, Surveyor Capital (a Citadel company), TCG X, Terra Magnum Capital Partners, Woodline Partners, and co-founder and strategic partner Schrödinger.
– Existing investors also participated in the financing, including Eight Roads, F-Prime Capital Partners, Qiming Venture Partners, Sequoia Capital China, TF Capital and Wuxi AppTec.

Visus Therapeutics Raises $20M in Funding

– Visus Therapeutics from Seattle develops innovative ophthalmic therapies to improve vision for people around the world.
– The company raised $20m in funding.
– The round was led by LSP in Amsterdam with participation from Sage Partners of Hong Kong, Johnson & Johnson Innovation -JJDC, Inc. and other inside investors.
– The new investment will be used to advance its clinical and commercial efforts for lead asset BRIMOCHOL under investigation for presbyopia as well as new research and development activities in its drug development pipeline.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Sage Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: